Law Daily Report

Verve Therapeutics Pauses Gene-Editing Trial Due to Side Effects

  • 📰 futurism
  • ⏱ Reading Time:
  • 5 sec. here
  • 12 min. at publisher
  • 📊 Quality Score:
  • News: 40%
  • Publisher: 68%

Health News

Verve Therapeutics,Gene-Editing Trial,Side Effects

The experimental biotech startup Verve Therapeutics has paused the first phase of a human gene-editing trial due to strange side effects in a patient. The trial aims to reduce heart-attack-causing cholesterol in patients with familial hypercholesterolemia. Verve's proposed solution is to genetically alter the cholesterol-managing PCSK9 gene using 'VERVE-101' serum. However, a patient enrolled in the trial passed away from a heart attack last year.

The experimental biotech startup Verve Therapeutics has paused the first phase of a buzzy human gene-editing trial due to strange side effects in a patient. The trial, dubbed the 'Heart-1' trial, aims to use gene editing to reduce heart-attack-causing cholesterol in patients with familial hypercholesterolemia. Verve's proposed solution is to inject 'VERVE-101,' a serum designed to genetically alter the cholesterol-managing PCSK9 gene and lower fatty LDL molecules.

However, a patient enrolled in the trial passed away from a heart attack last year

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 85. in LAW

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Viking Therapeutics' Weight-loss Tablet Shows Promise in Small StudyViking Therapeutics' experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial, meeting Wall Street expectations...
Source: Medscape - 🏆 386. / 55 Read more »